Brain-derived neurotrophic factor

Drug Profile

Brain-derived neurotrophic factor

Alternative Names: BDNF; Brain-derived growth factor

Latest Information Update: 02 Feb 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Max Planck Institute of Experimental Medicine
  • Developer Amgen; Medtronic; Regeneron Pharmaceuticals; Sumitomo Pharmaceuticals
  • Class Nerve growth factors
  • Mechanism of Action Neuron stimulants; TrkB receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Amyotrophic lateral sclerosis

Most Recent Events

  • 02 Feb 2001 Discontinued-Clinical for Amyotrophic lateral sclerosis in Japan (SC)
  • 02 Feb 2001 Discontinued-II for Amyotrophic lateral sclerosis in USA (Intrathecal)
  • 02 Feb 2001 Discontinued-II for Amyotrophic lateral sclerosis in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top